="/Images/box-checked.jpg" alt="Checkbox checked">

144: Remarks and Signature

Remarks

3 E SHARES OUTSTANDING BASED ON ORDINARY SHARES AS OF SEPTEMBER 30 24 SHARES SOLD WERE TO COVER OBLIGATIONS UNDER A 10B5 1 PLAN DIRECTIVE

Date of Notice

11/20/2024

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

08/13/2024

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

CONFORMED SIGNATURE ON FILE

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

TEVA Teva Pharmaceutical Industries Ltd

144: Remarks and Signature

ATTENTION:

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Latest TEVA Messages

Loading Messages....

Teva Pharmaceutical Industries Ltd News

Loading Messages....

Your Recent History

Company

Business

Popular

Get The App

Trending Now

Toplists

Market Data

News

Trading Tools

Markets

Discover

Hot Features

Follow Feed

Options Flow

Monitor

TEVA Teva Pharmaceutical Industries Ltd

144: Remarks and Signature

ATTENTION:

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

Latest TEVA Messages

Loading Messages....

Teva Pharmaceutical Industries Ltd News

Loading Messages....

Your Recent History

Company

Business

Popular

Get The App

Go Ad-Free